← Back to blog

Technology Transfer Agreements: Types, Key Terms and How to Negotiate

November 14, 2026
Technology Transfer Agreements: Types, Key Terms and How to Negotiate

A technology transfer agreement is the contract that moves a technology, and the right to use it, from the party that owns it to the party that will develop it. For most universities, researchers and startups, that contract is a license. The terms you agree on scope, money and performance decide whether a discovery becomes a product or stalls in a file. We advise universities, researchers and founders on licensing agreement structuring, so this guide walks through the agreement types, the terms that carry the weight, and the order in which a deal usually comes together.

Techtransferadvisors
Shape Licensing Terms for Commercialization
Tech Transfer Advisors helps universities, researchers, and founders structure licensing agreements and navigate intellectual property strategy.
Visit

TL;DR

  • A technology transfer agreement is any contract that moves technology, know-how or materials between parties. WIPO treats formal technology transfer as happening through such contracts.
  • The license is the core document. It grants the right to make, use, sell or import, and the terms set how broad that right is.
  • Scope (exclusivity, field of use, territory), money (fees, royalties, patent costs) and performance milestones are the three groups of terms that matter most.
  • There is no standard agreement. Even university templates must be adapted to each deal and reviewed by an IP lawyer.
  • Federally funded inventions carry extra U.S. rules that shape who can get an exclusive license and on what conditions.

Table of Contents

What a technology transfer agreement is

Technology can move informally, through publications, conversations and people changing jobs. It moves formally through contracts. WIPO describes technology transfer agreements as the formal route, and it lists the common forms: assignments of IP rights, confidentiality agreements, collaborative and sponsored research agreements, consultancy agreements, material transfer agreements, contract research agreements, academic spin-off agreements and joint venture agreements.

The word "agreement" covers a lot of ground, which is why searches for technology transfer agreements, technology license agreements and technology licensing agreements all end up in the same place. In practice, the sequence looks like this: a confidentiality agreement lets two parties talk, a material transfer or research agreement lets them test, and a license lets one of them commercialize.

A license is the document most readers care about. The NIH Working Group on Research Tools describes a license as a negotiated contract in which the owner grants the right to make, use, sell or import the subject matter, and it becomes binding once signed. The University of Illinois puts the exchange plainly: the licensor grants rights, and the licensee takes on obligations and responsibilities to commercialize the IP. MIT's licensing office adds an important point for universities: a license transfers rights without relinquishing MIT's ownership.

If you want the wider picture of how a university moves research from lab to market, our guide to university tech transfer covers the process around the contract.

The main types of agreements and when each applies

Each agreement type answers a different question. Choosing the wrong one costs months, so it helps to match the document to the stage you are in.

AgreementWhat it doesTypical stage
Confidentiality (NDA)Protects information shared while two parties evaluate each otherBefore any evaluation
Material transfer agreement (MTA)Moves tangible research material for a defined research useEarly testing
Sponsored or joint research agreementFunds or shares research and sets who owns the resultsDevelopment
Option agreementReserves the right to negotiate a license for a limited timeEvaluation
License (exclusive or non-exclusive)Grants rights to commercialize the IPCommercialization
AssignmentTransfers ownership of the IP outrightSale of the asset
Spin-off agreementSets terms between an institution and a new company built on its technologyCompany formation
CRADALets a federal lab collaborate with outside partnersFederal collaboration

Utah State University's list of common agreement types matches this pattern: NDAs, IP licenses, inter-institutional agreements, joint research agreements and MTAs.

Licenses: exclusive, non-exclusive, express and option

Rutgers describes the licensing models a university typically offers. Exclusive and non-exclusive licenses are the familiar pair. An express license is a non-exclusive license on predetermined, non-negotiable terms, often used for software or copyrighted works. An option agreement lets a company evaluate a technology for a limited time while the university reserves the right to negotiate a license with it later. For an early-stage founder, an option is often the right first step: it buys time to test the market before committing to license fees.

Material transfer agreements

An MTA is easy to mistake for a license, and the difference matters. The NIH Working Group explains that an MTA moves tangible material for research use, and that MTAs tend to be shorter and more informal than licenses but are still enforceable. They record the research project, confidentiality, publication and liability. Georgetown's agreement flowchart calls an MTA a form of non-exclusive license for limited internal research use, and notes that joint publication rights are often included where scientifically applicable.

The practical consequence: an MTA lets a company look at your material. It does not let them build a product from it. If a company wants to commercialize, you need a license.

CRADAs with federal laboratories

If one party is a federal lab, the agreement may be a cooperative research and development agreement. U.S. Army technology transfer materials describe a CRADA as the tool a federal lab uses to perform collaborative R&D with academic and industrial partners, with the partner receiving a time-limited option to take an exclusive license to government rights in inventions made under the CRADA, within the field of the CRADA. The Department of Energy's order DOE O 483.1C, approved in 2026, sets CRADA policy and oversight requirements, including risk-based oversight, so check the current version of the order if your partner is a DOE lab.

The terms that decide a license

Every technology license agreement, whatever its length, answers the same three questions: what exactly is licensed, what does it cost, and what must the licensee do to keep it.

Scope: exclusivity, field of use and territory

Illinois lists exclusivity, field of use and territory as the scope terms of a license. They interact. A company may want exclusivity worldwide in every field, while the university or inventor would rather split the technology: one licensee for a diagnostic application, another for a therapeutic one, one for North America, another for Europe.

Berkeley's licensing office notes that company requests at the start of the process may already include exclusive and field-of-use rights. Treat those requests as an opening position. A narrower field of use, tied to what the licensee can realistically develop, keeps the remaining fields available for other partners.

Money: fees, royalties and patent costs

The University of Illinois describes the financial terms that may appear in a license: an initial license fee, royalties (a percentage of sales or a fee per unit sold, with rates that vary by industry and significance), sharing of sublicensing revenue, minimum royalties, and reimbursement of patent costs. MIT lists a similar set: an issue fee, an annual maintenance fee, milestone fees, royalties, patent cost reimbursement, sharing of sublicense or partnership income and, for a startup licensee, minority equity.

For a founder, the equity and cash mix is where cash flow gets decided. A startup with no revenue usually cannot carry a heavy upfront fee, so a lower issue fee paired with equity, milestone payments and a minimum annual royalty is a common shape. For a university, the same mix protects the return if the company succeeds, which lines up with MIT's stated goal of a fair and reasonable financial return for the institution and inventors if the technology succeeds.

Performance: diligence milestones and reporting

A license is not a gift of rights. Illinois describes performance, or diligence, milestones tied to periodic reporting and to the conditions under which the licensee keeps the license. Typical milestones include raising a defined amount of funding, completing a development stage, filing a regulatory submission or reaching a first sale by a given date.

Milestones protect the licensor from a licensee who holds a technology and does nothing with it. They protect the licensee too, when they are realistic. A milestone calendar written for a software product will break a medical device program. If your technology faces FDA review, build the schedule from the regulatory path. Our guides to medical device regulatory strategy and medical device commercialization show how long those stages tend to run.

Anticipating a pivot

Illinois also advises that license terms should account for the possibility that the licensee's strategy changes. Startups pivot. A field-of-use definition that is too tight may force an amendment the first time the company finds its real market. A definition that is too loose may block a better licensee later. Draft with the likely pivots in mind, not just the current plan.

How a deal comes together

University licensing follows a recognizable path. Berkeley describes it this way: a company expresses interest, submits a commercialization plan, and negotiates a term sheet. Once the key terms are agreed, the technology licensing office prepares the agreement from its template and the parties sign.

In practice, we would break that into six steps.

  1. Define the asset. List the patents, applications, copyrights, data, materials and know-how that actually make the technology work. A license that names only the patent can leave out the know-how that makes it usable.
  2. Check the position. Confirm who owns what, whether sponsors or federal funding attach obligations, and whether other patents could block the product. IP due diligence and freedom to operate analysis answer these questions before you sign, when changes are still cheap.
  3. Test the market. A commercialization plan is only as credible as the market assessment behind it. A patent landscape analysis shows where the technology sits among existing filings and who the likely licensees are.
  4. Agree a term sheet. Settle exclusivity, field, territory, financial terms and milestones in a short document before lawyers draft the long one. Most disagreements surface here, which is the cheapest place to resolve them.
  5. Draft and negotiate the agreement. Move the term sheet into the full contract, adding warranties, indemnification, publication rights, termination and patent prosecution responsibility.
  6. Sign and manage. The signature starts the obligations: reports, payments and milestones need an owner on each side.

Why a template is not enough

WIPO is direct about this: there is no such thing as a standard technology transfer agreement. Universities may propose standard models as part of their IP policies, but those models must be adapted to each case, and parties should involve an IP lawyer from the start of negotiation and especially at signing. The templates sold online share the same limitation. They give you a shape, not the judgment about what your technology is worth and which terms fit your stage.

U.S. rules for federally funded and federal technology

When federal money paid for the research, the agreement is not purely a private bargain. Two parts of Title 35 of the U.S. Code do the most work here, and both are worth knowing before you negotiate.

  • Section 203 allows a federal agency to require or grant additional licenses when practical-application efforts have failed, when health or safety needs are unmet, or when public-use requirements are unmet. This is the march-in power. See the text of 35 U.S.C. Chapter 18.
  • Section 209 governs licensing of federally owned inventions. An agency may grant an exclusive or partially exclusive license only if conditions are met, including that exclusivity is a reasonable and necessary incentive, that the public will be served, that the applicant commits to achieving practical application within a reasonable time, and that the grant will not substantially lessen competition. The same chapter covers the requirement that U.S. interests in foreign commerce be enhanced when foreign patent coverage is involved.

The rules around them have also been updated. NIST's 2023 revisions, effective April 24, 2023, introduced a reporting requirement for federal agencies and clarified definitions, the march-in process, provisional patent filings, electronic Bayh-Dole reporting, and licensing and appeals processes, as published in the Federal Register.

What this means in practice: if your invention came from federally funded work, the diligence terms in your license are not just a commercial preference. They connect to the practical-application obligations the government expects. A licensee who plans to hold a technology without developing it creates risk for everyone involved.

Who needs what from the agreement

The same document looks different from each chair.

Universities want development for public benefit, compliance with federal and institutional policy, and a fair return. Their priorities are diligence milestones, patent cost recovery and clean reporting. A weak agreement leaves a technology parked and a licensee unaccountable.

Researchers and inventors want their work used, their publication rights protected and a share of the return. Read the agreement for what it says about publication, further research use and what happens if the licensee abandons the project.

Founders want the narrowest obligations they can carry and enough rights to raise money. Investors look closely at license terms: an unclear field, an exclusivity that can lapse or heavy early payments can stall a financing. A spinout license is also the base document of the company, so errors in it travel into every later round.

Who needs what from the agreement

Companies licensing university technology want freedom to develop and sell, clear ownership of improvements and a predictable cost structure, especially if the product faces regulation.

Perspective

Most licensing problems we see discussed are not drafting problems. They are problems of sequence: the agreement was written before anyone had assessed the market, mapped the patents or decided how the company would be funded.

Our team has worked inside major university technology transfer offices, in startup leadership, in federal grant review and in industry commercialization. That mix matters because a license reads differently from each of those seats, and a good agreement has to survive all of them: the university's policy, the founder's runway, the investor's diligence and the acquirer's review.

This is why we start with the commercial case and let the agreement follow it. We evaluate the commercial potential of the technology, shape the patent and licensing strategy, and structure the license so that scope, financial terms and milestones fit the product's real development path. Legal drafting is coordinated with a dedicated IP law partner, so the business terms and the legal text are built together instead of reconciled at the end.

A technology transfer agreement is the moment research becomes an asset. It deserves the same planning as the science behind it.

the author

How we can help

If you are structuring a license, forming a spinout or preparing a university technology for market, our services cover IP, patent strategy and licensing, spinout formation, life sciences and medical device commercialization, engineering technology transfer, funding strategy including SBIR/STTR and non-dilutive grants, go-to-market planning and investor introductions. Legal matters are coordinated with our IP law partner. Pricing is scoped to the engagement.

Techtransferadvisors

To discuss your technology and the agreement it needs, start at Tech Transfer Advisors.

FAQ

What is the difference between a technology transfer agreement and a license agreement?

"Technology transfer agreement" is the broad term for any contract that moves technology, know-how or materials between parties, including research agreements, MTAs and assignments. A license is one type: it grants the right to make, use, sell or import the technology while the owner keeps title. In university settings, the license is usually the agreement that enables commercialization.

What is a material transfer agreement?

An MTA governs the transfer of tangible research material from a provider to a recipient for the recipient's research. It records the project, confidentiality, publication and liability terms. It is shorter than a license and does not grant commercial rights, so a company that wants to build a product needs a license as well.

What terms should a technology license agreement cover?

At minimum: what is licensed, exclusivity, field of use and territory, the financial terms (fees, royalties, minimum royalties, sublicense income and patent costs), diligence milestones with reporting, and what happens on termination. Warranties, indemnification, publication rights and responsibility for patent prosecution complete the picture.

Can I use a template for a technology transfer agreement?

A template can show the structure, but WIPO states that no standard technology transfer agreement exists and that models must be adapted to each case. Have an IP lawyer involved from the start of negotiation and at signing. Our team coordinates the commercial structure with a dedicated IP law partner.

Do federal funding rules affect my license?

Yes, when federal money supported the invention or the technology is federally owned. Title 35 allows agencies to require additional licenses in certain circumstances and sets conditions for exclusive licenses to federally owned inventions. Reporting and march-in procedures were revised in 2023, so the diligence terms in your license should reflect them.

Sources